Table 3.
Plasma levels of TAMX and 4-OHT in BALB/c mice when comparing the two different routes of administration.
| Types of Formulations | Dose Administered (µg) |
Tamoxifen (ng/mL) |
% of TAMX Compared to Dose Administered | 4-OHT (ng/mL) |
% of 4-OHT Compared to Dose Administered |
|---|---|---|---|---|---|
| Control | ND | - | - | - | - |
| Topical Pure EO | - | - | - | - | - |
| Oral TAMX | 120 | 325.21 ± 3.78 | 0.27 | 634.42 ± 7.54 | 0.53 |
| DLT (85:15) + 4-OHT Transfersome | 100 | BQL | - | 32.45 ± 0.48 *** | 0.03 |
| DLT + EO (85:15) + 4-OHT Transfersome | 100 | BQL | - | 10.24 ± 0.07 *** | 0.01 |
*** p < 0.0001, significant value against oral TAMX and between DLT (85:15) + 4-OHT and DLT + EO (85:15) + 4-OHT. Values are the mean ± SD (n = 6). BQL—below the limit of quantification; EO—emu oil; DLT—deformable liposomes; and DLT + EO—deformable liposomes with emu oil.